Journal of Pharmacy and Pharmacology
First published: 4 December 2017
Jennifer Powley, Craig Russell
Objective: The aim of the work was to produce an ISMN solution developed to be safer and more appropriate for patient use compared to the current specials formulation.
Methods: Excipients were selected following pre-formulation screening; assessing safety, water solubility, pH range of activity and incompatibilities. Generally Recognised As Safe (GRAS) listing, The Food and Drug Administration (FDA) approval as well as pharmacopoeias were considered. Excipient inclusion was kept to a minimum.